Abstract：
:Premature mortality due to cardiovascular disease in those with schizophrenia is the largest lifespan disparity in the US and is growing; adults in the US with schizophrenia die, on average, 28 years earlier than those in the general population. The rate of smoking prevalence among individuals with schizophrenia is estimated to be from 64 to 79%. Smokers with schizophrenia have historically been excluded from most large nicotine-dependence treatment studies. However, converging evidence indicates that a majority of smokers with schizophrenia want to quit smoking, and that available pharmacotherapeutic smoking cessation aids are well tolerated by this population of smokers and are effective when combined with behavioral treatment. The aim of this review is to present updated evidence for safety and efficacy of smoking cessation interventions for those with schizophrenia spectrum illness. We also highlight implications of the very low abstinence rates for smokers with schizophrenia who receive placebo plus behavioral treatment in randomized trials, and review treatment approaches to address the high rate of rapid relapse observed upon pharmacologic treatment discontinuation in this population. Recommendations for monitoring for treatment-emergent nicotine withdrawal symptoms, side effects, and effects of cessation on antipsychotic medication are also provided. Smokers with schizophrenia spectrum disorders should be encouraged to quit smoking and should receive varenicline, bupropion with or without nicotine replacement therapy (NRT), or NRT, all in combination with behavioral treatment for at least 12 weeks. Maintenance pharmacotherapy may reduce relapse and improve sustained abstinence rates. Controlled trials in smokers with schizophrenia consistently show no greater rate of neuropsychiatric adverse events with pharmacotherapeutic cessation aids than with placebo.
journal_name
CNS Drugsjournal_title
CNS drugsauthors
Cather C,Pachas GN,Cieslak KM,Evins AEdoi
10.1007/s40263-017-0438-8subject
Has Abstractpub_date
2017-06-01 00:00:00pages
471-481issue
6eissn
1172-7047issn
1179-1934pii
10.1007/s40263-017-0438-8journal_volume
31pub_type
杂志文章,评审相关文献
CNS DRUGS文献大全abstract：:Anticonvulsant hypersensitivity syndrome (AHS) is a rare, but potentially fatal, adverse reaction that occurs in patients, including children, who are treated with anticonvulsants. During metabolism of the anticonvulsant, toxic arene-oxide compounds are produced. AHS is associated with both cutaneous and systemic symp...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200216030-00006
更新日期：2002-01-01 00:00:00
abstract：:NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions. ...
journal_title：CNS drugs
pub_type： 已发布勘误
doi：10.1007/s40263-018-0595-4
更新日期：2019-01-01 00:00:00
abstract：BACKGROUND:When otherwise unexplained, syncope in patients with Alzheimer's disease may be attributed to bradycardia caused by cholinesterase inhibitors. We studied prospectively the clinical events and cardiovascular changes occurring during treatment with donepezil in patients with Alzheimer's disease. METHODS:Conse...
journal_title：CNS drugs
pub_type： 临床试验,杂志文章
doi：10.2165/00023210-200620050-00005
更新日期：2006-01-01 00:00:00
abstract：:For nearly 50 years, antidepressant drugs have been the first-line treatment for various forms of depression. Despite their widespread use, these medications have significant shortcomings, in particular problems of patient compliance due to adverse effects. The introduction of new formulations of existing antidepressa...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200418080-00003
更新日期：2004-01-01 00:00:00
abstract：BACKGROUND:No head-to-head clinical trials have been published comparing guanfacine extended release (GXR) and atomoxetine (ATX): two nonstimulants approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). However, other study designs or methods could be used to indirectly compare these two medicat...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.1007/s40263-013-0102-x
更新日期：2013-11-01 00:00:00
abstract：:Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of condition...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-013-0041-6
更新日期：2013-03-01 00:00:00
abstract：:Insomnia, an inability to initiate or maintain sleep, affects approximately one-third of the American population. Conventional benzodiazepines, such as triazolam and midazolam, were the treatment of choice for short-term insomnia for many years but are associated with adverse effects such as rebound insomnia, withdraw...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200317070-00004
更新日期：2003-01-01 00:00:00
abstract：:Much work has been carried out in recent years showing that elevated glutamate levels in the extracellular environment of the central nervous system play a pivotal role in neurodegeneration in acute CNS injuries. With the elucidation of the mechanism governing glutamate excitotoxicity, researchers are devising therape...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-015-0225-3
更新日期：2015-02-01 00:00:00
abstract：:Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disorder most commonly caused by a deletion or mutation in the survival motor neuron 1 (SMN1) gene, which leads to insufficient levels of survival motor neuron (SMN) protein. In such patients, SMN protein production relies on the SMN2 gene. Nusi...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-018-0545-1
更新日期：2018-07-01 00:00:00
abstract：:The aim of this review is to provide clinicians with a picture of the mechanisms by which: histamine and histaminergic agonists act on the vestibular system both peripherally and centrally; and histaminergic agonists and antagonists interfere with the recovery process after peripheral vestibular lesion. We have focuse...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200115110-00004
更新日期：2001-01-01 00:00:00
abstract：:Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Varenicline was an effective aid to smoking cessation and was generally well tolerated in clinical trials, although more data are needed regarding the ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/11204710-000000000-00000
更新日期：2010-09-01 00:00:00
abstract：:Assessing the risk of stroke in persons with migraine is complicated by the intricate relationship between these two conditions. Both migraine and stroke are common and co-morbidity may, in some cases, be coincidental. Given the overlap of clinical symptoms in stroke and migraine, each condition may also mimic the oth...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200519080-00004
更新日期：2005-01-01 00:00:00
abstract：OBJECTIVES:Atomoxetine is commonly used to treat attention-deficit hyperactivity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine. METHODS:The records of ...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.2165/11590450-000000000-00000
更新日期：2011-06-01 00:00:00
abstract：:The eating disorders anorexia nervosa and bulimia nervosa present with comorbidity in a number of important areas, including depression, bipolar disorder, anxiety disorders (obsessive-compulsive disorder, panic disorder, social anxiety disorder and other phobias, and post-traumatic stress disorder) and substance abuse...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200620080-00004
更新日期：2006-01-01 00:00:00
abstract：:New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200418140-00005
更新日期：2004-01-01 00:00:00
abstract：:The kynurenine pathway constitutes the main route of tryptophan degradation and generates the production of several neuroactive compounds; quinolinic acid is an excitotoxic NMDA receptor agonist, 3-hydroxykynurenine is a free-radical generator and kynurenic acid (KYNA) is an antagonist at glutamate and nicotinic recep...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200923020-00001
更新日期：2009-01-01 00:00:00
abstract：:Spinal cord injury (SCI) has a number of severe and disabling consequences, including chronic pain, and around 40% of patients develop persistent neuropathic pain. Pain following SCI has a detrimental impact on the patient's quality of life and is a major specific healthcare problem in its own right. Thus far, there i...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200822060-00002
更新日期：2008-01-01 00:00:00
abstract：BACKGROUND:Responses to atomoxetine vary for individual patients with attention-deficit/hyperactivity disorder (ADHD). However, we do not know whether any factors can be used to reliably predict how individuals with ADHD will respond to treatment. OBJECTIVE:Our objective was to evaluate background variables that facil...
journal_title：CNS drugs
pub_type： 临床试验,杂志文章
doi：10.1007/s40263-016-0323-x
更新日期：2016-04-01 00:00:00
abstract：:Diclofenac potassium powder for oral solution (Voltfast(®), Catafast(®), Cambia(®); hereafter referred to as diclofenac potassium powder) is a non-steroidal anti-inflammatory drug (NSAID), and is indicated for the acute treatment of migraine. This article reviews the pharmacological properties of diclofenac potassium ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-014-0186-y
更新日期：2014-08-01 00:00:00
abstract：:Alzheimer's disease (AD) is the most prevalent dementia in the world. Its cause(s) are presently largely unknown. The most common explanation for AD, now, is the amyloid cascade hypothesis, which states that the cause of AD is senile plaque formation by the amyloid β peptide, and the formation of neurofibrillary tangl...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.1007/s40263-020-00737-1
更新日期：2020-07-01 00:00:00
abstract：:Oxcarbazepine (Trileptal, Timox) is structurally related to carbamazepine and has anticonvulsant activity. Studies suggest that the anticonvulsant activity of oxcarbazepine is mediated via the blocking of neuronal ion channels. In patients aged <18 years, the efficacy of oxcarbazepine monotherapy was similar to that o...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.2165/00023210-200418010-00006
更新日期：2004-01-01 00:00:00
abstract：:The issue of antipsychotic treatment during pregnancy is subject to substantial uncertainty and some controversy among healthcare providers, specifically pertaining to second-generation antipsychotics (SGAs) that are subject to a large gap in safety data during pregnancy compared with antidepressants. The amount of sa...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-018-0517-5
更新日期：2018-04-01 00:00:00
abstract：:Attention-deficit/hyperactivity disorder, or ADHD, is the most frequently occurring neurobiological disorder in childhood and is defined by symptoms of inattention and/or hyperactivity and impulsivity that are excessive when compared with other individuals at the same developmental level. ADHD can be successfully trea...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-013-0130-6
更新日期：2014-02-01 00:00:00
abstract：:The common strategy to treat a migraine attack as soon as it begins, made for classical acute antimigraine treatments such as ergotamine and analgesics, has not been transposed to the triptans. The recommendation to delay triptan intake until headache intensity is at least moderate is merely a habit generated by the p...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.2165/00023210-200115080-00001
更新日期：2001-01-01 00:00:00
abstract：:Despite several decades of research, the characteristics distinguishing atypical depression from other depressive subtypes remain ambiguous. Multiple lines of evidence support the designation of atypical depression as a scientifically and clinically relevant subtype, including differences in hormonal responses, brain ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/11310990-000000000-00000
更新日期：2009-12-01 00:00:00
abstract：:Given the high heritability of the disorder, attention-deficit hyperactivity disorder (ADHD) is common among parents of children with ADHD. Parental ADHD is associated with maladaptive parenting, negative parent-child interaction patterns and a diminished response to behavioural parent training. We describe our previo...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.2165/11633910-000000000-00000
更新日期：2012-09-01 00:00:00
abstract：:Postherpetic neuralgia, which occurs most typically in older persons, is one of the most common and serious complications of herpes zoster (or shingles). It is a chronic neuropathic pain syndrome and remains one of the most difficult pain disorders to treat. Known beneficial agents include antidepressants, antiepilept...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200317110-00001
更新日期：2003-01-01 00:00:00
abstract：:Hashimoto's encephalopathy is a term used to describe an encephalopathy of presumed autoimmune origin characterised by high titres of antithyroid peroxidase antibodies. In a similar fashion to autoimmune thyroid disease, Hashimoto's encephalopathy is more common in women than in men. It has been reported in paediatric...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200721100-00002
更新日期：2007-01-01 00:00:00
abstract：BACKGROUND:The introduction of second-generation antipsychotics (SGAs) over the past 2 decades generated considerable optimism that better antipsychotic treatments for schizophrenia and bipolar disorder were possible. SGAs offer several tolerability benefits over first-generation antipsychotics (FGAs), particularly wit...
journal_title：CNS drugs
pub_type： 杂志文章,meta分析,评审
doi：10.2165/11634500-000000000-00000
更新日期：2012-09-01 00:00:00
abstract：BACKGROUND:A recent large database analysis raised concerns of potential acute kidney injury (AKI) risk associated with antipsychotics. However, whether individual atypical and typical antipsychotics are associated with differential AKI risks has not been investigated. OBJECTIVE:The current study compared the risks of...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.1007/s40263-017-0421-4
更新日期：2017-04-01 00:00:00
